- Report
- October 2025
- 193 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 189 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 186 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 199 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 193 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 185 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 190 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 197 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 189 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 197 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 191 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 197 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 186 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 182 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 189 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 187 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 181 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 195 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 182 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 198 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP

The Companion Diagnostics market is a subset of the biotechnology industry that focuses on the development and commercialization of diagnostic tests that are used to identify patients who are likely to benefit from a particular therapeutic. These tests are used to identify the presence of a specific biomarker or genetic mutation that is associated with a particular therapeutic. The Companion Diagnostics market is driven by the increasing demand for personalized medicine, which is tailored to the individual patient's genetic makeup. This has led to the development of more sophisticated tests that can detect a wider range of biomarkers and mutations.
The Companion Diagnostics market is highly competitive, with a number of companies offering a range of tests. Examples of companies in the market include Roche Diagnostics, Abbott Laboratories, Qiagen, Illumina, and Thermo Fisher Scientific. Show Less Read more